Blood Immunology & Cellular Therapy
Издатель: Elsevier · ISSN 3050-5976 · 52 статей
- Harnessing Antibody-Dependent Cellular Phagocytosis in Human iPSC-Derived Macrophages for Cancer Therapy
- Duffy null status predicts severe neutropenia after ciltacabtagene autoleucel but not other BCMA therapies in myeloma
- Plasma proteomics reveals a low-expression immune phenotype in long-term pediatric hematopoietic cell transplantation survivors
- Expansion of minor PNH-phenotype cell populations within myeloid progenitors after CAR T-cell therapy
- Anti-CD38 therapy for the treatment of autoimmune neutropenia
- Development of TCR-NK cells as an off-the-shelf cell therapy against HCMV
- Polarized CAR-T9 immunotherapy prolongs B-cell depletion in a mouse model of systemic lupus erythematosus
- False Positive HIV-1 NAAT screening results after CAR-T therapy: A single institution, retrospective study
- Heme-Induced Terminal Differentiation Impairs CAR T Cell Fitness
- Should frontline Hodgkin lymphoma therapy differ based on validated genetic, immunologic, or biochemical biomarkers?
- Tracking B-cell depletion and reconstitution using next-generation immunosequencing
- Reduced TCF-1 expression after hematopoietic cell transplantation restricts the T-cell response to vaccination
- Optimized tandem BCMA-specific CAR T cells designed to minimize tonic signaling and off-target toxicity
- CD22 CAR linker, hinge, and transmembrane domains affect ligand-dependent protein interactions and in-human performance
- Steroid exposure is associated with cytomegalovirus reactivation after CAR T-cell therapy for large B-cell lymphomas
- Incidence and risk factors for hypogammaglobulinemia after CD19 CAR T-cell therapy
- Long-acting IL-7 (NT-I7, efineptakin alfa) after CD19 CAR T-cell therapy for large B-cell lymphoma: a phase 1b trial
- B-cell repertoire maturation as a biomarker for immune reconstitution after hematopoietic stem cell transplantation
- Late-onset central nervous system Toxoplasma gondii infection after CAR T-cell therapy
- Impact of infusion time on post–CAR T-cell survival in B-ALL
- A dysfunctional IL-10–producing memory CD8+ T-cell population is associated with severe CAR T-cell neurotoxicity
- Epcoritamab and glofitamab as bridging therapy prior to CAR T-cell therapy in relapsed/refractory large B-cell lymphoma